Compare AISP & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AISP | PMVP |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | 63 | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.7M | 76.8M |
| IPO Year | N/A | 2020 |
| Metric | AISP | PMVP |
|---|---|---|
| Price | $2.52 | $1.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 467.9K | 384.7K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $222.88 | N/A |
| Revenue Next Year | $5.36 | N/A |
| P/E Ratio | $3.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.03 | $0.83 |
| 52 Week High | $7.20 | $1.88 |
| Indicator | AISP | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 54.73 | 50.61 |
| Support Level | $2.07 | $1.37 |
| Resistance Level | $2.82 | $1.50 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 61.36 | 28.12 |
Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture. Airship AI's software allows customers to view structured data both in real-time as well as to conduct searches on the structured data at a later point in time.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.